Axiome is a EU-sovereign software platform designed to support the exploration, interpretation, and collaboration around complex biomedical datasets, with an initial focus on immunology and multi-omics research.
Today, biomedical research teams work with fragmented toolchains: data is processed in pipelines, analyzed in notebooks or scripts, and interpreted through static outputs such as figures, slides, or PDF reports. While these tools handle computation and storage, they do not preserve interpretive context, reasoning, or decision rationale, making collaboration, reproducibility, and reuse across teams or institutions difficult—especially in regulated or publicly funded environments.
Axiome addresses this gap by positioning itself above storage, pipelines, and execution platforms, as a collaborative interpretation and knowledge layer.
Concretely, Axiome provides:
Interactive cohort exploration for multi-omics and immunology datasets, enabling structured comparison, stratification, and visualization of results without custom scripting.
Shared analytical workspaces where hypotheses, annotations, intermediate conclusions, and assumptions are explicitly captured and reviewed, rather than remaining implicit or lost after delivery.
AI-assisted interpretation support, grounded in curated scientific references and project-specific context, designed to help explain results and structure documentation—without automating scientific decisions.
Governance-by-design foundations, including EU-hosted infrastructure, clear data ownership boundaries, access control, audit trails, and reproducibility baselines aligned with FAIR principles.
Axiome is developed as Research Use Only (RUO) in its initial phases. It does not make clinical claims, perform autonomous reasoning, or provide medical decision support. Instead, it enables research teams, CROs, biotech R&D groups, and public institutions to transform dispersed analyses into shared, auditable scientific knowledge.
Over time, the same foundation allows organizations to capitalize validated interpretations, building durable internal knowledge assets rather than isolated analyses—while preserving a controlled trajectory toward more institutional and regulated use cases if and when the intended use evolves.
